Alnylam initiates Phase 2 trial of mivelsiran in Down syndrome-associated Alzheimer’s disease
ALNY•cAPPricorn-1 enrollment completed
Enrollment completed in the Phase 2 cAPPricorn-1 study of mivelsiran in cerebral amyloid angiopathy; initial results are expected in 2028.
Phase 1 data showed strong CSF reductions
Phase 1 mivelsiran data in early-onset Alzheimer’s showed no increased ARIA signal; mean maximum CSF reductions reached 89.9% for sAPPβ.
Phase 2 trial initiated in Down syndrome-associated Alzheimer’s disease
Alnylam initiated a Phase 2 trial of mivelsiran in Down syndrome-associated early-stage Alzheimer’s disease, expanding its clinical Alzheimer’s program.
